� HMO halts Bextra prescriptions Jan. 31: Kaiser Permanente is halting prescriptions for the painkiller Bextra, saying the drug may be unsafe and could increase the risk of heart attacks.
- Kaiser Permanente, the nation's largest not-for-profit managed-care provider, has stopped prescribing Bextra until tests show whether the painkiller is safe.
The decision came amid "compelling" evidence of heightened heart risks associated with Bextra and a similar drug called Vioxx that manufacturer Merck & Co. pulled from the market in September, according to a company memo Kaiser issued late Friday.
Kaiser spokeswoman Beverly Hayon said the policy, which Kaiser is calling a moratorium, represents the first time the health system's doctors had decided to stop dispensing a drug that was approved by the Food and Drug Administration.
The Oakland-based HMO, hospital and clinic network, which serves 8.5 million patients in nine states and the District of Columbia, plans to stop filling new prescriptions for Bextra on Feb. 1 and on March 1 for refills.
Risks vs. benefits Physicians will be notified with suggestions for alternative medicines they can prescribe.
Bextra, made by Pfizer Inc., is most often recommended for arthritis patients.
"This is not a drug that saves lives," said Dr. Sharon Levine, who oversees medication usage for Kaiser Permanente's Northern California division.
The moratorium will last at least six months or "until the FDA and/or Pfizer can provide substantiated evidence to support the cardiovascular safety" of Bextra, the memo said.
The Kaiser doctors who reviewed Bextra's "safety profile" cited several studies that have raised concerns about whether the drug might increase the risk of heart attacks.